Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE Study)

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Hasegawa, Yoshie ^a   Tanino, Hirokazu ^b   Horiguchi, Jun ^c   Miura, Daishu ^d   Ishikawa, Takashi ^e   Hayashi, Mitsuhiro ^f   Takao, Shintaro ^g   Kim, Seung Jin ^h   Yamagami, Kazuhiko ⁱ   Miyashita, Masaru ^j   Konishi, Muneharu ^k   Shigeoka, Yasushi ^l   Suzuki, Masato ^m   Taguchi, Tetsuya ⁿ   Kubota, Tomoyuki ^o   Akazawa, Kouhei ^p   Kohno, Norio ^q   Rokutanda, Nana ^c   Tanaka, Takahiro ^r   Mizumoto, Sachiko ^k   Wakita, Kazuyuki ^l   Kunihisa, Tomonari ^l   Yamada, Kimito ^f   Kaise, Hiroshi ^f   Hirokaga, Koichi ^g   Tane, Kaori ^g   Sakurai, Teruhisa ^s   Nishimura, Akimasa ^t   more..

^a National Hospital Organization   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c GUNMA UNIVERSITY HOSPITAL   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

^g HYOGO CANCER CENTER   (Japan)

^h OSAKA UNIVERSITY   (Japan)

ⁱ Shinko Hospital   (Japan)

^j Konan Medical Center   (Japan)

^k Hyogo Prefectural Nishinomiya Hospital   (Japan)

^l YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^m TEIKYO UNIVERSITY   (Japan)

ⁿ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^o Kamiiida Daiichi General Hospital   (Japan)

^p NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^q KOBE KAISEI HOSPITAL   (Japan)

^r Naga Municipal Hospital   (Japan)

^s WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^t HIROSAKI UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIAN; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HER2 NEGATIVE BREAST CANCER; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROTO ONCOGENE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; GENES, ERBB-2; HUMANS; IMIDAZOLES; MIDDLE AGED; NEOADJUVANT THERAPY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84955488881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143643     Document Type: Article

References (17)

1. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11:421-428. doi: 10.1016/s1470-2045(10)70054-1 PMID: 20362507
2. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog. 2011; 10:2. doi: 10.4103/1477-3163.75723 PMID: 21297922
3. Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol. 2014; 25:998-1004. doi: 10.1093/annonc/mdu102 PMID: 24585721
4. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013; 24:398-405. doi: 10.1093/annonc/mds277 PMID: 23047045
5. Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, et al. Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Res. 2013; 73: S4-07. doi: 10.1158/0008-5472.sabcs13-s4-07
6. Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, et al. Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Res. 2013; 73: S4-07. doi: 10.1158/0008-5472.sabcs13-s4-07
7. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011; 127:429-438. doi: 10.1007/s10549-011-1429-y PMID: 21394500
8. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365:1396-1405. doi: 10.1056/NEJMoa1105195 PMID: 21995387
9. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer. 2010; 102:1099-1105. doi: 10.1038/sj.bjc.6605604 PMID: 20234364
10. Fehm T, Zwirner M, Wallwiener D, Seeger H, Neubauer H. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer. 2012; 12:308. doi: 10.1186/1471-2407-12-308 PMID: 22824103
11. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002; 4:30-34. PMID: 11879557
12. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360:679-691. doi: 10.1056/NEJMoa0806285 PMID: 19213681
13. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011; 12:631-641. doi: 10.1016/s1470-2045(11)70122-x PMID: 21641868
14. Green JR, Guenther A. The backbone of progress-preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol. 2011; 77(Suppl 1):S3-s12. doi: 10.1016/s1040-8428(11)70003-8 PMID: 21353178
15. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005; 23:3314-3321. doi: 10.1200/jco. 2005.05.116 PMID: 15738536
16. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer. 2010; 102:1010-1017. doi: 10.1038/sj.bjc.6605579 PMID: 20160726
17. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010; 126:522-532. doi: 10.1002/ijc.24756 PMID: 19621384